T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
 - EconoTimes)
MONTREAL, May 01, 2018 -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments related to the approval of EGRIFTA®.
At the time of approval of EGRIFTA® on November 10, 2010, the FDA requested that the company conduct two large safety clinical trials.
The FDA determined that these two large-scale post-approval clinical trials are no longer required as the current labeling adequately reflects the safety profile of EGRIFTA®. The FDA also concluded that the size of the HIV patient population with lipodystrophy did not make such a requirement feasible.
In its most recent audited financial statements, for the year ended November 30, 2017, Theratechnologies estimated that the post-approval commitments would require an additional investment of US$13 million, which will no longer be required.
About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
Media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236
